Rovin Capital UT ADV Purchases Shares of 120,562 DaVita Inc. (NYSE:DVA)

Rovin Capital UT ADV bought a new stake in DaVita Inc. (NYSE:DVA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 120,562 shares of the company's stock, valued at approximately $18,442,000. DaVita accounts for 5.9% of Rovin Capital UT ADV's investment portfolio, making the stock its 2nd biggest position. Rovin Capital UT ADV owned 0.15% of DaVita as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. UMB Bank n.a. grew its stake in DaVita by 65.5% during the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after purchasing an additional 76 shares in the last quarter. Copia Wealth Management acquired a new position in DaVita during the 4th quarter worth approximately $30,000. SBI Securities Co. Ltd. purchased a new stake in shares of DaVita in the 4th quarter valued at approximately $41,000. Coppell Advisory Solutions LLC lifted its position in shares of DaVita by 50.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock worth $45,000 after purchasing an additional 100 shares during the last quarter. Finally, Canada Post Corp Registered Pension Plan acquired a new position in shares of DaVita during the fourth quarter worth $55,000. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Stock Performance

DVA traded down $4.02 during trading on Wednesday, hitting $142.69. The stock had a trading volume of 831,042 shares, compared to its average volume of 809,204. DaVita Inc. has a twelve month low of $131.76 and a twelve month high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.20 and a current ratio of 1.25. The company's 50-day moving average price is $139.87 and its 200 day moving average price is $149.37. The firm has a market capitalization of $10.77 billion, a P/E ratio of 14.14, a PEG ratio of 1.01 and a beta of 1.11.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. DaVita had a return on equity of 176.11% and a net margin of 6.63%. The company had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.22 billion. During the same quarter in the previous year, the company earned $2.26 EPS. The firm's revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities research analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Truist Financial cut their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research note on Monday, May 19th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $164.50.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.